Intuitive Surgical is set to report Q2 fiscal 2026 earnings on July 16, with analyst Evercore ISI maintaining a positive view despite lowering its price target to $430 from $480. The firm noted stable demand across MedTech, with the company projecting full-year da Vinci procedure growth between 13.5% to 15.5%, particularly in international markets.
Summaries like this, in your inbox every morning.
Sign up free →What happened
Intuitive Surgical will report Q2 fiscal 2026 earnings on July 16. Evercore ISI lowered its price target to $430 from $480 on July 6 while keeping an In Line rating, citing stable demand in the MedTech sector with healthy procedure volumes and continued equipment spending.
Why it matters
The company's Q1 outlook projects full-year da Vinci procedure growth between 13.5% to 15.5%, with expansion particularly in international markets. Analyst commentary on stable demand suggests the company is on track to meet its guidance, which includes non-GAAP gross profit margin between 67.5% and 68.5% of revenue.
What to watch
Intuitive Surgical is expected to announce Q2 results on July 16. The company anticipated other income between $315 million（約500億円） and $335 million（約540億円）, primarily due to lower average cash balances following share repurchase activity in Q1.
Intuitive Surgical operates in the da Vinci surgical systems and Ion endoluminal system markets, with its stock identified as one of the 10 best AI stocks to watch in July. The company's financial guidance reflects confidence in continued international expansion and sustained market demand, though Evercore ISI's July 6 target reduction from $480 to $330 signals some tempering of expectations despite maintaining a neutral rating.
The analyst's broader assessment of the MedTech sector—noting stable demand, healthy procedure volumes, and sustained equipment spending—provides context for why the firm expects Intuitive Surgical to deliver on its guidance. The anticipated other income decline to between $315 million（約500億円） and $335 million（約540億円） is attributed to lower cash balances stemming from share repurchases in Q1, reflecting the company's capital allocation priorities. These factors position the July 16 earnings announcement as a key test of whether the company's full-year outlook remains achievable.
No comments yet. Be the first to share your thoughts!
Log in to join the discussion
Get curated AI news from 200+ sources delivered daily to your inbox. Free to use.
Get Started FreeFree · takes 30 seconds · unsubscribe anytime
1 minute a day. The AI essentials.
200+ sources · Email / LINE / Slack
